Clovis Oncology Company Profile (NASDAQ:CLVS)

About Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology logoClovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CLVS
  • CUSIP: 18946410
  • Web:
  • Market Cap: $4.15181 billion
  • Outstanding Shares: 44,772,000
Average Prices:
  • 50 Day Moving Avg: $80.71
  • 200 Day Moving Avg: $63.84
  • 52 Week Range: $13.43 - $96.92
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -43.76
  • P/E Growth: -0.48
Sales & Book Value:
  • Annual Revenue: $7.12 million
  • Price / Sales: 544.81
  • Book Value: $3.89 per share
  • Price / Book: 22.27
  • EBIDTA: ($262,070,000.00)
  • Return on Equity: -322.29%
  • Return on Assets: -62.07%
  • Debt-to-Equity Ratio: 1.62%
  • Current Ratio: 7.29%
  • Quick Ratio: 7.17%
  • Average Volume: 1.90 million shs.
  • Beta: 1.55
  • Short Ratio: 5.15
Frequently Asked Questions for Clovis Oncology (NASDAQ:CLVS)

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

How were Clovis Oncology's earnings last quarter?

Clovis Oncology, Inc. (NASDAQ:CLVS) issued its quarterly earnings results on Wednesday, May, 3rd. The company reported ($1.33) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.43) by $0.10. The business earned $7.05 million during the quarter, compared to analyst estimates of $6.04 million. View Clovis Oncology's Earnings History.

Where is Clovis Oncology's stock going? Where will Clovis Oncology's stock price be in 2017?

16 brokers have issued 1 year price targets for Clovis Oncology's stock. Their predictions range from $23.00 to $125.00. On average, they anticipate Clovis Oncology's share price to reach $79.50 in the next year. View Analyst Ratings for Clovis Oncology.

What are analysts saying about Clovis Oncology stock?

Here are some recent quotes from research analysts about Clovis Oncology stock:

  • 1. According to Zacks Investment Research, "Clovis got a huge boost with the FDA granting accelerated approval to its advanced ovarian cancer treatment, Rubraca in Dec 2016. Rubraca has bright prospects, given the tremendous demand for PARP inhibitors. Successful commercialization will significantly boost Clovis’ sales. Rubraca is also under review in the EU for a comparable indication. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. Promising progression-free survival and safety results from the ARIEL3 maintenance study is expected to help expand Rubraca’s label. However, with just one approved product in the portfolio, Clovis is heavily dependent on Rubraca for growth, which concerns us. Rubraca is also set to face intense competition from currently marketed PARP inhibitors. Loss estimates have widened lately ahead of the Q2 results. Clovis has a mixed earnings surprise record in the recent quarters." (7/13/2017)
  • 2. Cann analysts commented, "We are initiating coverage of Clovis Oncology, a recently commercial-stage biotechnology company, with a Perform rating. We anticipate Clovis will continue to develop its commercial drug, Rubraca (already approved for third-line ovarian cancer), in additional indications. Rubraca (rucaparib) is a PARP inhibitor for the treatment of ovarian cancer. As a therapeutic class, PARP inhibitors—including FDA-approved Lynparza (olaparib) and Zejula (niraparib)—are designed to exploit a synthetically lethal situation in tumors that lack proper DNA repair mechanisms." (6/22/2017)
  • 3. Goldman Sachs Group, Inc. (The) analysts commented, "AZN (covered by Keyur Parekh) presented data from a Ph3 SOLO-2 maintenance ovarian cancer trial of Lynparza (PARP inhibitor) on March 14 at the SGO conference, which we believe has implications for CLVS (lead marketed drug Rubraca is also a PARP). CLVS, AZN and TSRO (not covered) all have PARP inhibitors that they are evaluating for use in the maintenance treatment of ovarian cancer." (3/15/2017)
  • 4. Stifel Nicolaus analysts commented, "This price assumes about a 40% market share for rucaparib throughout addressable ovarian cancer (OC). However, in deriving this target, we include sales in the maintenance setting for ovarian cancer with a weighting of 75% (some risk remains to ARIEL3) and note that full weighing of this unapproved usage would suggest a fair value of about $104. Furthermore, inclusion of sales in mCRPC, which we consider highly promising but where large trials are just starting, suggests a fair value for Clovis shares of about $182. We consider most of the ongoing trials for rucaparib to be relatively low risk, but with several other players also competing for each indication we believe a takeout price of about 50% of our best case scenario makes sense." (1/23/2017)

Who are some of Clovis Oncology's key competitors?

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the folowing people:

  • M. James E. Barrett Ph.D., Independent Chairman of the Board
  • Patrick J. Mahaffy, President, Chief Executive Officer, Director
  • Daniel W. Muehl, Senior Vice President of Finance, Principal Accounting Officer and Principal Financial Officer
  • Gillian C. Ivers-Read, Executive Vice President - Technical Operations, Chief Regulatory Officer
  • Lindsey Rolfe BSc, MB ChB, MRCP, F, Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer
  • C. Dale Hooks, Senior Vice President, Chief Commercial Officer
  • Brian G. Atwood, Independent Director
  • James C. Blair Ph.D., Independent Director
  • Keith T. Flaherty M.D., Independent Director
  • Ginger L. Graham, Independent Director

Who owns Clovis Oncology stock?

Clovis Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.28%), Capital Impact Advisors LLC (0.03%), Insight Capital Research & Management Inc. (0.02%), Aperio Group LLC (0.01%), Legacy Private Trust Co. (0.01%) and Conservest Capital Advisors Inc. (0.01%). Company insiders that own Clovis Oncology stock include Erle T Mast, Gillian C Ivers-Read and Lindsey Rolfe. View Institutional Ownership Trends for Clovis Oncology.

Who sold Clovis Oncology stock? Who is selling Clovis Oncology stock?

Clovis Oncology's stock was sold by a variety of institutional investors in the last quarter, including Capital Impact Advisors LLC and Quantitative Systematic Strategies LLC. View Insider Buying and Selling for Clovis Oncology.

Who bought Clovis Oncology stock? Who is buying Clovis Oncology stock?

Clovis Oncology's stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Insight Capital Research & Management Inc., Legato Capital Management LLC, Bank of Montreal Can and Aperio Group LLC. View Insider Buying and Selling for Clovis Oncology.

How do I buy Clovis Oncology stock?

Shares of Clovis Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clovis Oncology's stock price today?

One share of Clovis Oncology stock can currently be purchased for approximately $86.64.

MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  291 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  513
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Clovis Oncology (NASDAQ:CLVS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $79.50 (8.24% downside)

Analysts' Ratings History for Clovis Oncology (NASDAQ:CLVS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/18/2017Credit Suisse Group AGSet Price TargetBuy$107.00LowView Rating Details
7/7/2017GabelliInitiated CoverageBuy$125.00HighView Rating Details
6/23/2017Oppenheimer Holdings, Inc.Initiated CoverageMarket PerformLowView Rating Details
6/22/2017CannInitiated CoverageMarket PerformLowView Rating Details
6/22/2017SunTrust Banks, Inc.Reiterated RatingBuyLowView Rating Details
6/20/2017J P Morgan Chase & CoReiterated RatingOverweight$72.00 -> $111.00HighView Rating Details
6/20/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$67.00 -> $90.00HighView Rating Details
6/20/2017Janney Montgomery ScottUpgradeNeutral -> BuyMediumView Rating Details
6/20/2017Bank of America CorporationLower Price TargetBuy$103.00 -> $75.00HighView Rating Details
6/20/2017Morgan StanleyReiterated RatingOverweight$79.00HighView Rating Details
6/19/2017Leerink SwannBoost Price TargetOutperform$85.00 -> $114.00HighView Rating Details
6/19/2017Stifel NicolausBoost Price TargetBuy$86.00 -> $125.00HighView Rating Details
6/19/2017Chardan CapitalUpgradeSell -> Neutral$36.00 -> $50.00HighView Rating Details
3/28/2017Piper Jaffray CompaniesSet Price TargetBuy$77.00LowView Rating Details
12/21/2016WallachBeth CapitalBoost Price TargetHold$22.00 -> $49.00N/AView Rating Details
8/24/2016MizuhoBoost Price TargetNeutral$15.00 -> $23.00N/AView Rating Details
(Data available from 7/22/2015 forward)


Earnings History for Clovis Oncology (NASDAQ:CLVS)
Earnings by Quarter for Clovis Oncology (NASDAQ:CLVS)
Earnings History by Quarter for Clovis Oncology (NASDAQ CLVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017Q1 2017($1.43)($1.33)$6.04 million$7.05 millionViewListenView Earnings Details
2/22/2017Q416($1.65)($1.83)$0.08 millionViewListenView Earnings Details
11/3/2016Q316($1.95)($1.70)ViewListenView Earnings Details
8/8/2016Q216($2.13)($2.07)ViewListenView Earnings Details
5/5/2016Q116($2.39)($2.17)ViewListenView Earnings Details
2/25/2016Q415($2.39)($2.23)ViewListenView Earnings Details
11/5/2015Q315($2.07)($2.62)ViewListenView Earnings Details
8/6/2015Q215($2.11)($2.10)$1.17 millionViewListenView Earnings Details
5/6/2015Q115($1.78)($1.86)$13.60 millionViewListenView Earnings Details
2/25/2015Q414($1.41)($1.62)ViewListenView Earnings Details
11/6/2014Q314($1.03)($1.17)ViewListenView Earnings Details
8/7/2014Q214($0.93)($1.03)$13.60 millionViewListenView Earnings Details
5/8/2014Q114($0.85)($0.91)$13.60 millionViewListenView Earnings Details
2/27/2014Q4($0.78)($0.92)ViewListenView Earnings Details
10/31/2013Q313($0.68)($0.68)ViewListenView Earnings Details
8/1/2013Q2 2013($0.65)($0.72)ViewListenView Earnings Details
5/7/2013Q1 2013($0.60)($0.60)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Clovis Oncology (NASDAQ:CLVS)
2017 EPS Consensus Estimate: ($4.89)
2018 EPS Consensus Estimate: ($2.18)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.53)($1.53)($1.53)
Q2 20173($1.30)($1.18)($1.23)
Q3 20173($1.16)($1.05)($1.11)
Q4 20173($1.13)($0.87)($1.02)
Q1 20181($0.67)($0.67)($0.67)
Q2 20181($0.53)($0.53)($0.53)
Q3 20181($0.53)($0.53)($0.53)
Q4 20181($0.45)($0.45)($0.45)
(Data provided by Zacks Investment Research)


Dividend History for Clovis Oncology (NASDAQ:CLVS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Clovis Oncology (NASDAQ:CLVS)
Insider Ownership Percentage: 17.40%
Institutional Ownership Percentage: 89.68%
Insider Trades by Quarter for Clovis Oncology (NASDAQ:CLVS)
Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)
Insider Trades by Quarter for Clovis Oncology (NASDAQ:CLVS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/17/2017Gillian C Ivers-ReadInsiderSell3,000$91.56$274,680.00View SEC Filing  
6/15/2017Gillian C Ivers-ReadInsiderSell3,000$61.82$185,460.00View SEC Filing  
5/15/2017Gillian C Ivers-ReadInsiderSell3,000$47.39$142,170.00View SEC Filing  
4/17/2017Gillian C Ivers-ReadInsiderSell3,000$56.02$168,060.00View SEC Filing  
3/15/2017Gillian C Ivers-ReadInsiderSell3,000$66.99$200,970.00View SEC Filing  
11/2/2015Erle T. MastCFOSell3,000$105.56$316,680.00View SEC Filing  
10/28/2015Lindsey RolfeinsiderSell4,000$98.02$392,080.00View SEC Filing  
10/15/2015Gillian C Ivers-ReadInsiderSell3,000$91.91$275,730.00View SEC Filing  
10/5/2015Lindsey RolfeinsiderSell4,000$93.04$372,160.00View SEC Filing  
10/1/2015Erle T. MastCFOSell3,000$90.22$270,660.00View SEC Filing  
9/18/2015Gillian C Ivers-ReadInsiderSell3,000$112.56$337,680.00View SEC Filing  
9/1/2015Erle T. MastCFOSell3,000$79.51$238,530.00View SEC Filing  
7/1/2015Erle T MastCFOSell3,000$85.70$257,100.00View SEC Filing  
6/1/2015Erle T MastCFOSell3,000$88.78$266,340.00View SEC Filing  
5/15/2015M James BarrettDirectorSell2,424$92.43$224,050.32View SEC Filing  
4/1/2015Erle T MastCFOSell3,000$71.25$213,750.00View SEC Filing  
3/9/2015Erle T MastCFOSell9,000$78.84$709,560.00View SEC Filing  
3/5/2015James C BlairDirectorSell8,528$77.70$662,625.60View SEC Filing  
1/16/2015Steven L HoerterInsiderSell10,000$67.00$670,000.00View SEC Filing  
12/11/2013Erle MastCFOSell50,000$52.78$2,639,000.00View SEC Filing  
12/5/2013Thorlef SpickschenDirectorSell9,000$56.10$504,900.00View SEC Filing  
6/5/2013Andrew R AllenInsiderSell22,594$68.54$1,548,592.76View SEC Filing  
6/4/2013M James BarrettDirectorSell2,483$70.80$175,796.40View SEC Filing  
6/4/2013Parters Vii L P DomainMajor ShareholderSell159,192$64.58$10,280,619.36View SEC Filing  
6/4/2013Steven L HoerterInsiderSell10,000$73.06$730,600.00View SEC Filing  
3/6/2013Parters Vii L P DomainMajor ShareholderSell250,000$24.59$6,147,500.00View SEC Filing  
8/16/2012Edward J MckinleyDirectorBuy9,701$15.50$150,365.50View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Clovis Oncology (NASDAQ:CLVS)
Latest Headlines for Clovis Oncology (NASDAQ:CLVS)
DateHeadline logoClovis Oncology, Inc. (NASDAQ:CLVS) PT Set at $107.00 by Credit Suisse Group - July 20 at 12:58 AM logoClovis Oncology, Inc. (CLVS) Raised to "Buy" at Vetr Inc. - July 20 at 12:26 AM logo3 Stocks at 52-Week Highs Still Worth Buying - July 18 at 6:48 PM logoClovis Oncology, Inc. (NASDAQ:CLVS) Insider Gillian C. Ivers-Read Sells 3,000 Shares - July 17 at 10:14 PM logo$13.65 Million in Sales Expected for Clovis Oncology, Inc. (NASDAQ:CLVS) This Quarter - July 16 at 8:00 AM logo Analysts Expect Clovis Oncology, Inc. (NASDAQ:CLVS) to Post -$1.29 EPS - July 14 at 6:20 PM logoClovis (CLVS) Focuses on Rubraca Launch and Label Expansion ... - Nasdaq - July 14 at 4:26 AM logoClovis (CLVS) Focuses on Rubraca Launch and Label Expansion - July 13 at 6:23 PM logoZacks Investment Research Lowers Clovis Oncology, Inc. (NASDAQ:CLVS) to Hold - July 13 at 3:06 PM logoHere's Why Clovis Oncology Inc. Jumped 70% in June - Motley Fool - July 8 at 4:57 PM logoHere's Why Clovis Oncology Inc. Jumped 70% in June - July 8 at 9:52 AM logoClovis Oncology, Inc. (NASDAQ:CLVS) Given Consensus Recommendation of "Buy" by Brokerages - July 7 at 11:58 AM logoClovis Oncology, Inc. (NASDAQ:CLVS) Coverage Initiated at Gabelli - July 7 at 10:52 AM logoNoteworthy ETF Outflows: XBI, CLVS, EXEL, ALXN - Nasdaq - July 5 at 5:58 PM logoStock Traders Purchase Large Volume of Clovis Oncology Call Options (CLVS) - July 5 at 7:16 AM logoThis Rebounding Pharma Stock May Launch Another Breakout Move - June 30 at 5:24 PM logoIs It Too Late to Buy Clovis Oncology Stock? - June 27 at 4:00 PM logoEquities Analysts Issue Forecasts for Clovis Oncology, Inc.'s Q2 2017 Earnings (CLVS) - June 26 at 7:08 AM logoClovis Oncology, Inc. (CLVS) to Post Q2 2017 Earnings of ($1.18) Per Share, Oppenheimer Holdings Forecasts - June 26 at 7:08 AM logoWhat To Expect From Clovis Oncology Following Rubraca Approval - Benzinga - June 24 at 3:02 AM logoHealthcare ETF (IYH) Hits New 52-Week High - June 23 at 4:58 PM logoWhat To Expect From Clovis Oncology Following Rubraca Approval - June 23 at 1:38 PM logoClovis Oncology, Inc. (CLVS) Earns Market Perform Rating from Analysts at Oppenheimer Holdings, Inc. - June 23 at 9:06 AM logoClovis Oncology (CLVS) Prices Upsized Offering at $88/Share - June 22 at 9:48 PM logoClovis Oncology, Inc. (CLVS) Coverage Initiated at Cann - June 22 at 5:27 PM logoClovis Oncology commencing $250 million stock offering - June 22 at 4:39 PM logoClovis Oncology Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock - June 22 at 11:05 AM logoClovis Oncology, Inc. (CLVS) Worth a Look: Stock Jumps 6.3% - June 22 at 11:05 AM logo$13.65 Million in Sales Expected for Clovis Oncology, Inc. (CLVS) This Quarter - June 22 at 10:24 AM logoSunTrust Banks, Inc. Reaffirms Buy Rating for Clovis Oncology, Inc. (CLVS) - June 22 at 10:22 AM logoBidaskClub Upgrades Clovis Oncology, Inc. (CLVS) to Buy - June 21 at 8:18 PM logoQ3 2017 EPS Estimates for Clovis Oncology, Inc. (CLVS) Lifted by Leerink Swann - June 21 at 8:36 AM logoClovis Oncology (CLVS) Prices Upsized Offering at $88/Share - - June 20 at 10:02 PM logoClovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock - June 20 at 10:02 PM logo Brokerages Expect Clovis Oncology, Inc. (CLVS) to Announce -$1.20 EPS - June 20 at 4:10 PM logoClovis Addresses Some Of The Company's Biggest Controversies - June 20 at 3:55 PM logoJ P Morgan Chase & Co Reiterates "Overweight" Rating for Clovis Oncology, Inc. (CLVS) - June 20 at 12:28 PM logoClovis Oncology, Inc. (CLVS) Stock Rating Upgraded by Janney Montgomery Scott - June 20 at 7:58 AM logoMid-Afternoon Market Update: Crude Oil Down Over 1%; Clovis Oncology Shares Spike Higher - Nasdaq - June 20 at 5:24 AM logoClovis Oncology Inc. (CLVS) Is Pulling Back After Stock Offering - June 20 at 12:23 AM logoBiotech stocks are having their best day since February - June 20 at 12:22 AM logoClovis Oncology Announces Proposed Offering of Common Stock - June 20 at 12:22 AM logoClovis Oncology to launch $250 mln stock offering - June 20 at 12:22 AM logoMid-Afternoon Market Update: Crude Oil Down Over 1%; Clovis Oncology Shares Spike Higher - Benzinga - June 19 at 7:22 PM logoWhy Clovis Oncology Inc (CLVS) Stock Just Shot 50% Higher - - June 19 at 7:22 PM logoHere's what's behind the biotech breakout - June 19 at 7:22 PM logoClovis Oncology Target of Unusually High Options Trading (CLVS) - June 19 at 5:38 PM logoClovis Oncology, Inc. (CLVS) Given New $114.00 Price Target at Leerink Swann - June 19 at 4:28 PM logoMid-Afternoon Market Update: Crude Oil Down Over 1%; Clovis Oncology Shares Spike Higher - June 19 at 4:22 PM logoClovis Oncology's Rubraca Notches Key Trial Win - June 19 at 2:34 PM



Clovis Oncology (CLVS) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by Staff